

AD _____

Award Number: W81XWH-12-1-0268

TITLE: Inhibition of Ovarian Cancer Chemoresistance and Metastasis with Antagonists of Hyaluronan-CD44-CD147 Interactions

PRINCIPAL INVESTIGATOR: Bryan P. Toole, Ph.D.

CONTRACTING ORGANIZATION: Medical University of South Carolina
Charleston, SC 29425

REPORT DATE: July 2013

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE July 2013		2. REPORT TYPE Annual		3. DATES COVERED 1 July 2012 – 30 June 2013	
4. TITLE AND SUBTITLE Inhibition of Ovarian Cancer Chemoresistance and Metastasis with Antagonists of Hyaluronan-CD44-CD147 Interactions				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-12-1-0268	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Bryan P. Toole E-Mail: toolebp@musc.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Medical University of South Carolina Charleston, SC 29425				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT The overall objectives of our work on human ovarian carcinoma cells are to determine the mechanisms whereby hyaluronan-CD44-CD147 interactions influence malignant cell behavior and therapy resistance, and to apply our findings to the improvement of therapy, in malignant ovarian carcinoma. In this grant period we have shown that small hyaluronan oligosaccharides, which have previously been shown to antagonize hyaluronan-receptor interactions, sensitize cisplatin-resistant human ovarian carcinoma cells to cisplatin treatment in a mouse xenograft model, as well as in cell culture. Hyaluronan oligosaccharide-decorated nanoparticles containing chemotherapeutic agents are in preparation for maximizing these effects. We have also shown that siRNAs against the hyaluronan receptor, CD44, and the regulator of hyaluronan synthesis, CD147, sensitize cisplatin-resistant ovarian carcinoma cells to cisplatin in cell culture. Nanoparticles containing these siRNAs are in preparation for use in vivo.					
15. SUBJECT TERMS Ovarian carcinoma; hyaluronan; CD147; CD44; drug resistance					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 10	19a. NAME OF RESPONSIBLE PERSON USAMRMC
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	8
Reportable Outcomes.....	8
Conclusion.....	8
References.....	9
Appendices.....	NA

INTRODUCTION

Our previous studies have shown that hyaluronan, the hyaluronan receptors CD44 or LYVE-1, and the Ig superfamily member CD147 act cooperatively to promote malignant and drug-resistant properties. This most likely occurs through assembly and/or stabilization of plasma membrane signaling complexes containing CD44 or LYVE-1 in association with CD147, receptor tyrosine kinases and transporters implicated in malignancy and resistance to therapies (Ghatak et al., 2005; Grass et al., 2012; Qin et al., 2011; Slomiany et al., 2009a; Slomiany et al., 2009b; Slomiany et al., 2009c). CD147 (emmprin; basigin) is a cell surface member of the Ig superfamily that induces expression of hyaluronan and matrix metalloproteinases, and promotes cell invasiveness, anchorage independent growth, drug resistance, and tumor growth and metastasis *in vivo* (Caudroy et al., 2002; Dai et al., 2013; Marieb et al., 2004; Zucker et al., 2001). We have shown recently that sub-populations of ovarian carcinoma cells, and other cancer cell types, with high expression of cell surface CD147 have similar properties to cancer stem cells, including enhanced levels of anchorage-independent growth, drug resistance and invasiveness (Dai et al., 2013).

Many of the activities of CD147 in cancer cells are dependent on hyaluronan-CD44 or LYVE-1 signaling (Ghatak et al., 2005; Marieb et al., 2004; Misra et al., 2003; Qin et al., 2011) and CD44 is one of the most common markers for carcinoma cancer stem cells (Zoller, 2011). The overall objectives of our work are to determine the mechanisms whereby hyaluronan-CD44-CD147 interactions influence malignant cell behavior and therapy resistance, and to apply our findings to the improvement of therapy, in particular in recurrent ovarian carcinoma. For example, we have found that multivalent interactions of hyaluronan polymer with CD44 are necessary for stabilizing CD44-CD147 signaling complexes, and that small, monovalent, hyaluronan oligosaccharides antagonize hyaluronan-receptor signaling by disrupting constitutive hyaluronan polymer-receptor interaction, thus leading to inhibition of oncogenic signaling pathways, chemoresistance and malignant characteristics (Ghatak et al., 2002; Ghatak et al., 2005; Gilg et al., 2008; Misra et al., 2006; Qin et al., 2011; Slomiany et al., 2009a; Slomiany et al., 2009b; Slomiany et al., 2009c). In particular we have found that treatment with small hyaluronan oligosaccharides is effective in sensitizing various types of drug-resistant cancer cells to chemotherapeutic agents (Gilg et al., 2008; Misra et al., 2005; Misra et al., 2003; Qin et al., 2011; Slomiany et al., 2009a). Most notably, these oligosaccharides inhibit tumor growth by drug-resistant cancer stem cell sub-populations obtained from human patient-derived ovarian carcinoma cells (Slomiany et al., 2009b).


Our aims for this grant are to establish efficacy for small hyaluronan oligosaccharides as chemo-sensitizing agents in xenograft models of human ovarian carcinoma cells, to determine whether siRNAs directed against CD44 and CD147 affect ovarian carcinoma chemoresistance and metastasis, and to explore mechanisms for increasing efficiency of delivery of these agents together with chemotherapeutic agents.

BODY

In this grant period, our major aim has been to assess various parameters of treatment with small hyaluronan oligosaccharides and siRNAs against CD44 and CD147 using the cisplatin-resistant human ovarian carcinoma cell line, A2780cp20. We chose this cell line since cisplatin is commonly used in first-line treatment of ovarian carcinoma patients. The results of these experiments will be used to guide our experiments with ovarian carcinoma cancer stem-like cells obtained from patient ascites fluids.

a) Chemo-sensitization by small hyaluronan oligosaccharides *in vitro*

In our preliminary experiments we showed that co-treatment with small hyaluronan oligosaccharides sensitized human ovarian carcinoma cells (SKOV-3 and PE04) to various chemotherapeutic agents, i.e. taxol, doxorubicin and cisplatin, in cell culture (Figure 1).



b) Chemo-sensitization by small hyaluronan oligosaccharides *in vivo*

Using intraperitoneal xenografts of cisplatin-resistant A2780cp20 human ovarian carcinoma cells, we have now shown that co-treatment with small hyaluronan oligosaccharides sensitizes these cells to treatment with cisplatin *in vivo* (Figure 2). The oligosaccharides also sensitized these cells to treatment with doxorubicin *in vivo* (Figure 2). Doses of cisplatin and doxorubicin were chosen to give sub-optimal responses when used alone. Co-treatment with the hyaluronan oligosaccharides plus either drug caused large decreases in tumor growth, as compared to drug treatment alone (Figure 2).

In collaboration with Dr. Anil Sood's group at MD Anderson, we have also prepared small hyaluronan oligosaccharide-decorated chitosan nanoparticles (Han et al., 2011), which will be used to determine whether these particles, with and without loading with cisplatin, doxorubicin or taxol, are more efficient than the same reagents in solution.

In addition, we have begun to prepare ovarian carcinoma cells from patient-derived ascites fluids by previously developed methods (Slomiany et al., 2009b), in order to test the effects of small hyaluronan oligosaccharides on cisplatin and taxol resistance in these cells.





Figure 2: Chemo-sensitization *in vivo* of cisplatin-resistant ovarian carcinoma cells with small hyaluronan oligosaccharides (oHA).


A2780cp20 human ovarian carcinoma cells (1×10^6 per mouse) were injected intraperitoneally. Groups of 5 mice were treated with vehicle (200ul saline) or the following reagents dissolved in 200ul saline: 10mg/kg oHA, 5mg/kg cisplatin (cis), 5mg/kg cisplatin + 10mg/kg oHA, 0.05mg/kg doxorubicin (dox), or 0.05mg/kg doxorubicin + 10mg/kg oHA. Treatments were administered intraperitoneally once per week for 4 weeks. The mice were then sacrificed and peritoneal tumors weighed. *p value <0.05

c) Chemo-sensitization by siRNAs against CD44 and CD147

Despite previous success in obtaining efficient knockdown in various cancer cell types with siRNAs against CD44 and CD147 (Ghatak et al., 2005; Grass et al., 2012; Misra et al., 2005; Qin et al., 2011; Slomiany et al., 2009c), we have had difficulties obtaining efficient knockdown in A2780cp20 cisplatin-resistant ovarian carcinoma cells. In recent attempts, we have succeeded in obtaining partial but significant knockdown (Figure 3). Using these conditions we have also shown partial effects of these siRNAs on cisplatin resistance in the A2780cp20 cells in culture (Figure 4).

In order to obtain more robust effects we are collaborating with Anil Sood's group at MD Anderson to encapsulate the siRNAs in liposomal nanoparticles. Similar particles have been used with considerable success in their studies of other anti-ovarian carcinoma siRNAs *in vitro* and *in vivo* (Landen et al., 2010; Mangala et al., 2009; Spannuth (Graybill) et al., 2011).





KEY RESEARCH ACCOMPLISHMENTS

1. Demonstration that small hyaluronan oligosaccharides sensitize cisplatin-resistant human ovarian carcinoma cells to cisplatin or doxorubicin treatment *in vivo*.
2. Demonstration that partial knockdown of CD44 or CD147 with siRNAs in cisplatin-resistant human ovarian carcinoma cells results in a partial increase in sensitivity to cisplatin treatment *in vitro*.

REPORTABLE OUTCOMES

None

CONCLUSIONS

We have shown that small hyaluronan oligosaccharides sensitize cisplatin-resistant human ovarian carcinoma cells to cisplatin treatment *in vivo*. Recurrence of ovarian cancer in patients who have been given standard-of-care cisplatin treatment is a major cause of patient morbidity. Thus further investigation of the effects of small hyaluronan oligosaccharides, especially with respect to efficiency of delivery, is an important future objective.

REFERENCES

- Caudroy, S., Polette, M., Nawrocki-Raby, B., Cao, J., Toole, B. P., Zucker, S. and Birembaut, P.** (2002). Emmprin-mediated MMP regulation in tumor and endothelial cells. *Clin Exp Metastasis* **19**, 697-702.
- Dai, L., Guinea, M. C., Slomiany, M. G., Bratoeva, M., Grass, G. D., Tolliver, L. B., Maria, B. L. and Toole, B. P.** (2013). CD147-dependent heterogeneity in malignant and chemoresistant properties of cancer cells. *Am J Pathol* **182**, 577-585.
- Ghatak, S., Misra, S. and Toole, B. P.** (2002). Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. *J Biol Chem* **277**, 38013-38020.
- Ghatak, S., Misra, S. and Toole, B. P.** (2005). Hyaluronan regulates constitutive ErbB2 phosphorylation and signal complex formation in carcinoma cells. *J Biol Chem* **280**, 8875-8883.
- Gilg, A. G., Tye, S. L., Tolliver, L. B., Wheeler, W. G., Visconti, R. P., Duncan, J. D., Kostova, F. V., Bolds, L. N., Toole, B. P. and Maria, B. L.** (2008). Targeting hyaluronan interactions in malignant gliomas and their drug-resistant multipotent progenitors. *Clin Cancer Res* **14**, 1804-1813.
- Grass, G. D., Bratoeva, M. and Toole, B. P.** (2012). Regulation of invadopodia formation and activity by CD147. *J. Cell Sci.* **125**, 777-788.
- Han, H. D., Mora, E. M., Roh, J. W., Nishimura, M., Lee, S. J., Stone, R. L., Bar-Eli, M., Lopez-Berestein, G. and Sood, A. K.** (2011). Chitosan hydrogel for localized gene silencing. *Cancer Biol Ther* **11**, 839-845.
- Landen, C. N., Jr., Goodman, B., Katre, A. A., Steg, A. D., Nick, A. M., Stone, R. L., Miller, L. D., Mejia, P. V., Jennings, N. B., Gershenson, D. M. et al.** (2010). Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. *Mol Cancer Ther* **9**, 3186-3199.
- Mangala, L. S., Han, H. D., Lopez-Berestein, G. and Sood, A. K.** (2009). Liposomal siRNA for ovarian cancer. *Methods Mol Biol* **555**, 29-42.
- Marieb, E. A., Zoltan-Jones, A., Li, R., Misra, S., Ghatak, S., Cao, J., Zucker, S. and Toole, B. P.** (2004). Emmprin promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. *Cancer Res* **64**, 1229-1232.
- Misra, S., Ghatak, S. and Toole, B. P.** (2005). Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. *J Biol Chem* **280**, 20310-20315.
- Misra, S., Ghatak, S., Zoltan-Jones, A. and Toole, B. P.** (2003). Regulation of multi-drug resistance in cancer cells by hyaluronan. *J Biol Chem* **278**, 25285-25288.
- Misra, S., Toole, B. P. and Ghatak, S.** (2006). Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells. *J Biol Chem* **281**, 34936-34941.
- Qin, Z., Dai, L., Bratoeva, M., Slomiany, M. G., Toole, B. P. and Parsons, C.** (2011). Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma. *Leukemia* **25**, 1598-1609.
- Slomiany, M. G., Dai, L., Bomar, P. A., Knackstedt, T. J., Kranc, D. A., Tolliver, L. B., Maria, B. L. and Toole, B. P.** (2009a). Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan-CD44 interactions with small hyaluronan oligosaccharides. *Cancer Res* **69**, 4992-4998.
- Slomiany, M. G., Dai, L., Tolliver, L. B., Grass, G. D., Zeng, Y. and Toole, B. P.** (2009b). Inhibition of functional hyaluronan-CD44 interactions in CD133-positive primary

human ovarian carcinoma cells by small hyaluronan oligosaccharides. *Clin Cancer Res* **15**, 7593-7601.

Slomiany, M. G., Grass, G. D., Robertson, A. D., Yang, X. Y., Maria, B. L., Beeson, B. and Toole, B. P. (2009c). Hyaluronan, CD44 and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. *Cancer Res.* **69**, 1293-1301.

Spannuth (Graybill), W. A., Mangala, L. S., Stone, R. L., Carroll, A. R., Nishimura, M., Shahzad, M. M., Lee, S. J., Moreno-Smith, M., Nick, A. M., Liu, R. et al. (2011). Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. *Mol Cancer Ther* **9**, 2377-2388.

Zoller, M. (2011). CD44: can a cancer-initiating cell profit from an abundantly expressed molecule? *Nat Rev Cancer* **11**, 254-267.

Zucker, S., Hymowitz, M., Rollo, E. E., Mann, R., Conner, C. E., Cao, J., Foda, H. D., Tompkins, D. C. and Toole, B. P. (2001). Tumorigenic potential of extracellular matrix metalloproteinase inducer (EMMPRIN). *Am J Pathol* **158**, 1921-1928.